The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as its popular weight-loss and diabetes shots ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Immunocore (IMCR) has appointed Travis Coy as EVP, CFO and Head of Corporate Development, effective January 1. He will become an Executive ...

Karyopharm Therapeutics Inc. (KPTI), a company focused on novel cancer therapies, said on Thursday that it has appointed Lori ...

Immunocore Holdings hired a non-executive director on its board as the company's chief financial officer. The U.K. biotechnology company Thursday said Travis Coy has been appointed CFO and head of ...

most recently served as CFO of Legend Biotech Corporation. Previously, she held leadership roles of increasing responsibility at Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer.

Eli Lilly has become one of the world's most influential ... On Dec. 9, Lilly's board of directors approved a $15 billion stock buyback program. CFO Lucas Montarce said of the share buyback ...

CFO Lucas Montarce said of the share buyback ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy.

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right ... Lilly's board of directors approved a $15 billion stock buyback program. CFO Lucas Montarce said of the share buyback ...

He had a 14-year career at Eli Lilly, including roles in corporate finance ... as well as working as a regional CFO in Europe. He left Lilly to move back to Canada and began working as a public ...